英夫利西单抗对克罗恩病不同治疗方案的疗效分析

发布时间：2018-09-11 17:20

【摘要】：一、目的：探讨英夫利西单抗治疗克罗恩病的疗效和安全性。方法:2011年l月-2013年10月24例在仁济医院接受英夫利西单抗治疗的24例克罗恩患者，应用5mg/kg静脉滴注第0、2、6周,以后每8周1次,维持30周,观察第6周及30周的疗效。结果：使用英夫利西单抗治疗6周后,患者的临床症状以及血液指标明显改善，治疗30周较6周临床症状进一步改善，，均无不良反应。结论：英夫利西单抗对克罗恩病的治疗效果明显且安全性可，应用30周较6周的疗效有进一步的改善。二、目的：英夫利西单抗单用及其联用硫唑嘌呤的疗效和安全性比较。方法：2011年l月-2013年10月仁济医院单用英夫利西单抗及其联用硫唑嘌呤治疗的各12例克罗恩病患者，英夫利西单抗单用(剂量：5mg/kg静脉滴注第0、2、6周，后每8周一次维持30周)，第二组在英夫利西单抗第6周加用硫唑嘌呤（剂量：1~2mg/kg/d)。结果：两组30周在临床症状和血液指标的上无显著差异。结论：英夫利西单抗单用及其联用硫唑嘌呤的疗效和安全性比较需要进一步的临床随访。三、目的：英夫利西单抗应用升阶梯和降阶梯治疗的疗效比较。方法：2011年l月-2013年10月仁济医院12例在疾病早期应用英夫利西单抗和9例传统治疗失败后应用英夫利西单抗的克罗恩病患者（剂量：5mg/kg静脉滴注第0、2、6周，以后每8周1次，维持30周）。结果：升阶梯和降阶梯两组的疗效比较没有明显的差异。结论：升降阶梯的治疗效果比较需进一步临床随访。
[Abstract]:Objective: to investigate the efficacy and safety of infliximab in the treatment of Crohn's disease. Methods: from January 2011 to October 2013, 24 patients with Crohn were treated with Infritemab in Renzi Hospital. The patients were treated with 5mg/kg intravenous drip for 6 weeks, followed by every 8 weeks for 30 weeks. The curative effect was observed at the 6th week and the 30th week. Results: after 6 weeks of treatment, the clinical symptoms and blood indexes of the patients were significantly improved, and the clinical symptoms were further improved at 30 weeks and 6 weeks after treatment, and no adverse reactions were found. Conclusion: the efficacy of infleximab in the treatment of Crohn's disease is obvious and safe, and the effect of 30 weeks treatment is better than that of 6 weeks. Objective: to compare the efficacy and safety of infliximab and its combination with azathioprine. Methods: from January 2011 to October 2013, 12 patients with Crohn's disease were treated with infliximab alone and 12 patients with Crohn's disease treated with azathioprine in Renzi Hospital from January 2011 to October 2013. The second group was treated with azathioprine (1 mg / kg / d) at the 6th week of Inflesi McAb. Results: there was no significant difference in clinical symptoms and blood indexes between the two groups at 30 weeks. Conclusion: the efficacy and safety of infliximab and its combination with azathioprine need further clinical follow-up. Objective: to compare the efficacy of infleximab in the treatment of ascending ladder and descending ladder. Methods: from January 2011 to October 2013, 12 patients with Crohn's disease were treated with infliximab at the early stage of the disease and 9 patients with Crohn's disease after the failure of traditional treatment. For 30 weeks). Results: there was no significant difference between the two groups. Conclusion: further clinical follow-up is needed to compare the therapeutic effect of elevating ladder.
【学位授予单位】：上海交通大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R574.62

【参考文献】